Cargando…
Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives
SIMPLE SUMMARY: Contrast imaging techniques play a pivotal role in the diagnosis and management of Intrahepatic cholangiocarcinoma (iCCA). There is an increasing interest in the specific imaging features which can predict tumor behavior or histologic subtypes. ABSTRACT: Intrahepatic cholangiocarcino...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341250/ https://www.ncbi.nlm.nih.gov/pubmed/37444503 http://dx.doi.org/10.3390/cancers15133393 |
_version_ | 1785072217898352640 |
---|---|
author | Cerrito, Lucia Ainora, Maria Elena Borriello, Raffaele Piccirilli, Giulia Garcovich, Matteo Riccardi, Laura Pompili, Maurizio Gasbarrini, Antonio Zocco, Maria Assunta |
author_facet | Cerrito, Lucia Ainora, Maria Elena Borriello, Raffaele Piccirilli, Giulia Garcovich, Matteo Riccardi, Laura Pompili, Maurizio Gasbarrini, Antonio Zocco, Maria Assunta |
author_sort | Cerrito, Lucia |
collection | PubMed |
description | SIMPLE SUMMARY: Contrast imaging techniques play a pivotal role in the diagnosis and management of Intrahepatic cholangiocarcinoma (iCCA). There is an increasing interest in the specific imaging features which can predict tumor behavior or histologic subtypes. ABSTRACT: Intrahepatic cholangiocarcinoma (iCCA) represents the second most common liver cancer after hepatocellular carcinoma, accounting for 15% of primary liver neoplasms. Its incidence and mortality rate have been rising during the last years, and total new cases are expected to increase up to 10-fold during the next two or three decades. Considering iCCA’s poor prognosis and rapid spread, early diagnosis is still a crucial issue and can be very challenging due to the heterogeneity of tumor presentation at imaging exams and the need to assess a correct differential diagnosis with other liver lesions. Abdominal contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) plays an irreplaceable role in the evaluation of liver masses. iCCA’s most typical imaging patterns are well-described, but atypical features are not uncommon at both CT and MRI; on the other hand, contrast-enhanced ultrasound (CEUS) has shown a great diagnostic value, with the interesting advantage of lower costs and no renal toxicity, but there is still no agreement regarding the most accurate contrastographic patterns for iCCA detection. Besides diagnostic accuracy, all these imaging techniques play a pivotal role in the choice of the therapeutic approach and eligibility for surgery, and there is an increasing interest in the specific imaging features which can predict tumor behavior or histologic subtypes. Further prognostic information may also be provided by the extraction of quantitative data through radiomic analysis, creating prognostic multi-parametric models, including clinical and serological parameters. In this review, we aim to summarize the role of contrast-enhanced imaging in the diagnosis and management of iCCA, from the actual issues in the differential diagnosis of liver masses to the newest prognostic implications. |
format | Online Article Text |
id | pubmed-10341250 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103412502023-07-14 Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives Cerrito, Lucia Ainora, Maria Elena Borriello, Raffaele Piccirilli, Giulia Garcovich, Matteo Riccardi, Laura Pompili, Maurizio Gasbarrini, Antonio Zocco, Maria Assunta Cancers (Basel) Review SIMPLE SUMMARY: Contrast imaging techniques play a pivotal role in the diagnosis and management of Intrahepatic cholangiocarcinoma (iCCA). There is an increasing interest in the specific imaging features which can predict tumor behavior or histologic subtypes. ABSTRACT: Intrahepatic cholangiocarcinoma (iCCA) represents the second most common liver cancer after hepatocellular carcinoma, accounting for 15% of primary liver neoplasms. Its incidence and mortality rate have been rising during the last years, and total new cases are expected to increase up to 10-fold during the next two or three decades. Considering iCCA’s poor prognosis and rapid spread, early diagnosis is still a crucial issue and can be very challenging due to the heterogeneity of tumor presentation at imaging exams and the need to assess a correct differential diagnosis with other liver lesions. Abdominal contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) plays an irreplaceable role in the evaluation of liver masses. iCCA’s most typical imaging patterns are well-described, but atypical features are not uncommon at both CT and MRI; on the other hand, contrast-enhanced ultrasound (CEUS) has shown a great diagnostic value, with the interesting advantage of lower costs and no renal toxicity, but there is still no agreement regarding the most accurate contrastographic patterns for iCCA detection. Besides diagnostic accuracy, all these imaging techniques play a pivotal role in the choice of the therapeutic approach and eligibility for surgery, and there is an increasing interest in the specific imaging features which can predict tumor behavior or histologic subtypes. Further prognostic information may also be provided by the extraction of quantitative data through radiomic analysis, creating prognostic multi-parametric models, including clinical and serological parameters. In this review, we aim to summarize the role of contrast-enhanced imaging in the diagnosis and management of iCCA, from the actual issues in the differential diagnosis of liver masses to the newest prognostic implications. MDPI 2023-06-28 /pmc/articles/PMC10341250/ /pubmed/37444503 http://dx.doi.org/10.3390/cancers15133393 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Cerrito, Lucia Ainora, Maria Elena Borriello, Raffaele Piccirilli, Giulia Garcovich, Matteo Riccardi, Laura Pompili, Maurizio Gasbarrini, Antonio Zocco, Maria Assunta Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives |
title | Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives |
title_full | Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives |
title_fullStr | Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives |
title_full_unstemmed | Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives |
title_short | Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives |
title_sort | contrast-enhanced imaging in the management of intrahepatic cholangiocarcinoma: state of art and future perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341250/ https://www.ncbi.nlm.nih.gov/pubmed/37444503 http://dx.doi.org/10.3390/cancers15133393 |
work_keys_str_mv | AT cerritolucia contrastenhancedimaginginthemanagementofintrahepaticcholangiocarcinomastateofartandfutureperspectives AT ainoramariaelena contrastenhancedimaginginthemanagementofintrahepaticcholangiocarcinomastateofartandfutureperspectives AT borrielloraffaele contrastenhancedimaginginthemanagementofintrahepaticcholangiocarcinomastateofartandfutureperspectives AT piccirilligiulia contrastenhancedimaginginthemanagementofintrahepaticcholangiocarcinomastateofartandfutureperspectives AT garcovichmatteo contrastenhancedimaginginthemanagementofintrahepaticcholangiocarcinomastateofartandfutureperspectives AT riccardilaura contrastenhancedimaginginthemanagementofintrahepaticcholangiocarcinomastateofartandfutureperspectives AT pompilimaurizio contrastenhancedimaginginthemanagementofintrahepaticcholangiocarcinomastateofartandfutureperspectives AT gasbarriniantonio contrastenhancedimaginginthemanagementofintrahepaticcholangiocarcinomastateofartandfutureperspectives AT zoccomariaassunta contrastenhancedimaginginthemanagementofintrahepaticcholangiocarcinomastateofartandfutureperspectives |